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Objectives: To estimate the future direct cost of OA in Canada using a population-based health micro-
simulation model of osteoarthritis (POHEM-OA).
Methods: We used administrative health data from the province of British Columbia (BC), Canada, a
survey of a random sample of BC residents diagnosed with OA (Ministry of Health of BC data), Canadian
Institute of Health Information (CIHI) cost data and literature estimates to populate a microsimulation
model. Cost components associated with pharmacological and non-pharmacological treatments, total
joint replacement (TJR) surgery, as well as use of hospital resources and management of complications
arising from the treatment of osteoarthritis (OA) were included. Future costs were then simulated using
the POHEM-OA model to construct proﬁles for each adult Canadian.
Results: From 2010 to 2031, as the prevalence of OA is projected to increase from 13.8% to 18.6%, the total
direct cost of OA is projected to increase from $2.9 billion to $7.6 billion, an almost 2.6-fold increase (in
2010 $CAD). From the highest to the lowest, the cost components that will constitute the total direct cost
of OA in 2031 are hospitalization cost ($2.9 billion), outpatient services ($1.2 billion), alternative care and
out-of-pocket cost categories ($1.2 billion), drugs ($1 billion), rehabilitation ($0.7 billion) and side-effect
of drugs ($0.6 billion).
Conclusions: Projecting the future trends in the cost of OA enables policy makers to anticipate the sig-
niﬁcant shifts in its distribution of burden in the future.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The direct costs associated with Osteoarthritis (OA) are signiﬁ-
cant compared to other musculoskeletal diseases due to high
prevalence of disease and high use of associated resources1,2. A
patient with OA, even in its early stages, consumes health careo: B. Sharif, Department of
ersity of Calgary, Room 3C64,
spital Drive NW, Calgary, AB
0-9574.
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ternational. Published by Elsevier Lresources at almost double the rate of the general population
without OA3. At the same time, OA's burden is escalating at a fast
rate due to the considerable rise in obesity and population aging4,5.
Estimating the direct cost of OA and its future trends has posed a
challenge to health economics researchers6,7. The majority of past
national cost-of-illness studies (COI) have utilized top-down and
prevalence-based methodologies that are deﬁned according to
health expenditure data and use of cross-sectional data1,7. These
types of studies have been criticized because of inconsistencies in
their estimates, their lack of ﬂexibility to be used in economic
evaluation studies, and their lack of ability to project cost in time
and across sub-populations6,8. For example, direct cost estimates of
OA in the US have been reported to have a 40-fold variation across
different studies6, between 13 and 185 billion dollars (2010 $US)5,9.
In Canada, the total direct cost of OA without out-of-pocket coststd. All rights reserved.
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according to different studies6,10. Incident-based or ‘bottom-up’
studies can be more accurate but due to a lack of appropriate
administrative data11, very few national incident based COI studies
have been conducted1.
Simulation modeling techniques and speciﬁcally micro-
simulation (MSM) can be used to project health indices across
heterogeneous populations. Suchmodels have been used in various
chronic conditions12 such as osteoporosis13 and diabetes14. The
capability of these types of models in projecting population de-
mographics and disease risk factors in addition to their ﬂexibility in
evaluating the effect of policies on disease burden makes MSM an
attractive epidemiological and economic modeling approach15. In
this study, we use the Population Health Microsimulation Model of
Osteoarthritis (POHEM-OA)16, a validated individual-level, contin-
uous-time simulation model to perform a COI study for projecting
the future direct costs of OA in Canada for the period of 2010e2031.Methods
The POHEM-OA model is based on a validated individual-level
simulation model developed by Statistics Canada for several
chronic conditions17. These models utilize an array of large data-
bases for demographic, immigration, mortality and morbidity sta-
tistics (Appendix A1). The POHEM-OA simulation model used in
this study is a discrete-event simulation model that generates the
probable time to OA-related events16. These continuous time var-
iables are generated according to the appropriate hazard distribu-
tions for events such as OA diagnoses or hip/knee total joint
replacement (TJR) surgery17. Fig. 1 shows the diagram of the
POHEM-OA model.Fig. 1. POHEM-OA: A population-based microsimulation model of osteoarthritis *. The re
model. Cylinders inside the ﬁgure are data sets used for estimating model parameters; NPH
Statistics Canada (ref*) ** CCHS-2001: Canadian Community Health Survey (54); ** *BCLHD: B
is linked to BCLHD and has drugs-related data for all BC population; HRQL: Health-relatedThe POHEM-OA model uses the Canadian Community Health
Survey (CCHS) in 2001 to sample individuals for its initial popula-
tion18. The main risk factors for the OA diagnosis in POHEM-OA are
age, sex and body mass index (BMI). The model simulates an in-
dividual's life history in terms of OA-related events through inter-
related stochastic processes; at each calendar year, the events are
assigned to individuals according to their characteristics, e.g., OA
diagnosis is determined based on age, sex and BMI of each indi-
vidual16 and BMI is modeled as an auto-regression model that in-
cludes age, sex, income, education, region, and previous BMI. The
progression of OA in POHEM-OA ismodeled in terms of patient ﬂow
in the healthcare system using BC administrative data. After an OA
diagnosis, the ﬁrst OA progression stage modeled is a visit to the
orthopedic surgeon (OS). There may have already been several
physician visits (GP, or specialist) by the time of the ﬁrst OS visit,
while most cases of OA never visit an OS. After the (OS) visit, pa-
tients may be hospitalized for a short stay and undergo an inpatient
procedure or they may be assigned for total knee or hip replace-
ment surgery (TJR). Further details of the POHEM-OA model are
discussed elsewhere16.Description of the cost algorithm
We developed the cost module of POHEM-OA that consists of
input parameters representing the per-patient and per patient-year
unit costs of the resources utilized by OA patients. In this cost
module, each individual is assigned a cost proﬁle that keeps track of
the values of that individual's characteristics as they change
throughout the simulation. To capture the heterogeneity among OA
populations and account for the variation in their resource utili-
zation, four types of cost factors have been deﬁned so thatctangle in the left represents the socio-demographic characteristics of individuals in the
S 1994e2004: National Population Health Survey, a longitudinal household survey by
ritish Columbia Population-based administrative data (same as PDBC) (84), PharmaNet
Quality of life.
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patient gets updated. Cost factors include age categories, sex, OA
stage, and time in each stage. OA stage is deﬁned by the OA-related
events with relation to the patient's ﬂow in the healthcare system:
stage 1 between OA diagnosis and OS visit; stage 2 between OS visit
and hip/knee TJR; stage 3 between primary hip/knee TJR and
revision TJR; stage 4 after revision hip/knee TJR. The time in each of
these disease stages is categorized as 0e2 years, 2e5 years and 5
years or more.
Cost components
The following cost components are included in our analysis: 1)
physician visits and other outpatient procedures, 2) hospitalization
and rehabilitation, 3) medications and 4) side-effects of OA drugs.
Details of each cost components and their corresponding data
sources are shown in Tables I and II. All costs were translated into
2010 $CAD using the overall Consumer Price Index (CPI) according
to Statistics Canada rates19. The total cost of OA in future years was
discounted back to 2010 Canadian dollars20.
Data sources
Themain data source for estimating the input parameters of this
study was the Population Data BC21e23, a pan-provincial population
health data service that provides access to the health care services'
databases for all BC residents registered with the province's pub-
licly funded universal insurance program. This includes hospitali-
zation episodes, physician visits, tests and other outpatient services
and drugs.Table I
Direct cost categories of OA and inﬂation rates implemented in the POHEM-OA direct co
Cost category Cost component Parameter Dat
esti
Hospitalization and
inpatient costs
Hip/knee TJR surgery Hazard rates of surgery by age
and sex
PDB
Average unit cost of surgery CIH
Number of surgeries per year
and future trend in surgery
rates
CJRR
Other in-patient
procedures for OA (non-
hip/knee TJR Surgery)
Average patient-year unit cost PDB
Average procedure costs CIH
Number of procedures per year St. P
(200
Physician and
outpatient care
costs
Physician visits andmedical
tests
Average patient-year unit costs PDB
Drugs Prescription drugs Average patient-year unit costs PDB
Over-the-counter drugs Average patient-year unit costs NPH
* PDBC: Population data BC from 1987-200328.
y CIHI-HP: Canadian Institute of Health Information hospitalization cost data in 20103
z CIHI-PSF: CIHI report on physician and surgeon fees from 2005-201035.
x CIHI-HPI: CIHI report on hospital price index33 for full time hospital employee wage
k CJRR: Canadian Joint Replacement Registry data for number of surgeries from 1996-
¶ St. Paul's hospital unit cost model in 200632.
# NPDB-PPI: National physician data base reported by CIHI on physician fee-for-servic
** CIHI-DER: CIHI-Drug Expenses Report34.
yy NPHS: National Population Health Survey used for estimating over-the-counter drugWe also used the British Columbia Ministry of Health's OA
(MOH-OA) survey24 to estimate the input parameters for alterna-
tive care categories, including physiotherapy, chiropractic, and
massage therapy (Table A14). Trends for the number of knee and
hip TJRs and their cost estimates were derived from the Canadian
Joint Replacement Registry (CJRR) data25 and Centre for Health
Information (CIHI) hospitalization cost data in 201126, respectively.
The St. Paul's Hospital cost model27 and the CIHI hospitalization
cost database26 were used to calculate hospitalization cost for
procedures other than hip and knee TJR. Price indexes for the
average hospitalization cost reported by Cost per Weighted Case
(CPWC) across Canada28, along with those for drugs29, physicians
and orthopaedic surgeons30,31 for the years 2003e2010 were taken
from the CIHI Price Index Reports, while the overall economy CPI
was used from the Statistics Canada report19. The Clinical Research
Ethics Board at the University of British Columbia provided ethics
approval for this study.Derivation of cost parameters
Physician, drugs and hospitalization (other than hip/knee TJR)
We have used Medical Services Plan (MSP) database of Popu-
lation Data BC from 1986/7 to 2003 to calculate the outpatient unit
costs of OA patients21. We have included physician's visits and
ambulatory services including x-rays, MRI, blood work, other
diagnostic tests and other types of services. All physician visits for
OA and OA-related inpatient procedures were included. For esti-
mating the drug cost, all OA-related drugs were categorized into
four types: acetaminophen, non-steroidal anti-inﬂammatory drugs
(NSAIDs), coxibs and opioids. A stratiﬁed random sample ofst module for publically funded cost components
a sources for cost
mation (year)
Cost component's inﬂation
index (annual inﬂation rate %)
Data sources for inﬂation
(year) [Reference]
C* (1987e2003)
IeHPy (2010) 1. Orthopedic surgeon fee-for
service price index (2.1%)
2. Surgical Implant inﬂation
rate (9.8%)
3. Hospital employee wage
index (3.6 %)
1. CIHI-PSFz (2005e2010)
2. Refer to [45]
3. CIHI-HPI (2007e2011)x
k(1996e2010)
C (2003) Hospital employee wage index
(3.6%)
CIHI-HPI (2007e2011)
I-HPI (2010)
aul's hospital¶
6)
C (2003) Physician fee-for service price
index (3.2%)
NPDB- PPI (2003e2008)#
C (2003) Prescription-based generic and
brand name drugs price index
(0.9%)
CIHI-DER** (2009e2012)
Syy (2006) Over-the-counter generic and
brand name drugs price index
(1.6%)
CIHI-DER (2009e2012)
1.
index from 2007 to 2011.
201030.
e price index from 2003-200836.
s cost for OA (unpublished data).
Table II
Direct cost categories of OA and inﬂation rates implemented in the POHEM-OA direct cost module for rehabilitation and out-of-pocket cost components
Cost category Cost component Parameter Data sources for the base-year
cost estimation (year)
Cost component inﬂation index
(annual inﬂation rate %)
Data source for inﬂation
(year) [Reference]
Rehabilitation and
home care costs
(after hip/knee
surgery)
Healthcare system paid
rehabilitation and
home care costs
Probability for home/hospital
discharge strategy
Oldmeadow et al. (2000)33 Hospital employee wage index
(3.6 %)
CIHI-HPI (2007e2011)*
Unit costs for each discharge
strategy
Coyte et al. (2001)32 Consumer Price Index (CPI) for
overall economy
CANSIM (2005e2011)y
Out-of-pocket-cost
during rehab
Average patient-year unit costs Refer to45 Consumer Price Index (CPI) for
overall economy
CANSIM (2005e2011)
Formal caregiver
and other costs
Formal caregiver,
transportation and
community costs
Probability and unit costs Gupta et al. (2005)34 Consumer Price index (CPI) for
overall economy
CANSIM (2005e2011)
Alternative care
costs
Physical therapy,
Chiropractic's,
acupuncture and other
complementary care
services
Utilization rates MOH-OAz (2007) e e
Per-service Fees MSPx (2003) Physician fee-for service price
index (3.2%)
NPDB- PPI (2003
e2008)k
Side effect of drug's Cardiovascular disease
(CVD's), Stroke,
Gastrointestinal (GI),
Dyspepsia
Utilization of drug use PDBC¶ (2003) e e
Probability of side effects for
each type of drug
Literature review (2010)
[unpublished]
e e
Life time cost for CVD and
stroke, Incidence-based cost
for GI and dyspepsia
Refer to45 Consumer Price Index (CPI) for
overall economy
Consumer Price Index
(CPI) for overall
economy
* CIHI-HPI: CIHI Report on Hospital Price Index33 for full time hospital employee wage index from 2007 to 2011.
y CPI for overall economy was calculated based on an exponential extrapolation from historical data (2005e2011) from Statistics Canada ‘s CANSIM CPI Report26.
z MOH-OA: British Columbia Ministry of Health's OA survey29.
x MSP fees in 2003: Medical Services Plan fees from PDBC28.
k NPDB-PPI: National physician data base reported by CIHI on physician fee-for-service price index from 2003-200835.
¶ PDBC: Population data BC from 1987-200328.
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Population Data BC23 to estimate input parameters associated with
the per patient-year OA drug costs. We have included different OA-
related drug types and assumed that all prescription-based drugs
are included in the healthcare-system paid cost categories for OA
(Table A5). For the over-the-counter drug costs, we used the utili-
zation rates and costs for the over-the-counter drug categories from
National Population Health survey for acetaminophen, some
NSAIDS and some opioids (unpublished data). For hospital pro-
cedures (inpatient procedures) other than hip/knee surgeries, up to
25 diagnosis codes and a maximum of 12 procedure codes, along
with the type of procedure (primary, revision or emergency), were
found for each admission date on hospital discharge summaries22.
Details of methods for estimating input parameters are provided in
Appendix A1.
Hip/knee TJR surgery costs
A separate analysis was performed to estimate per-patient hip/
knee TJR costs. To this end, we needed to estimate the costs of both
a knee/hip TJR and the number of TJR events in the simulation
model. For the age-speciﬁc unit cost of a hip/knee TJR we used CIHI
hospitalization data26. The overall cost of a TJR equals the weighted
average of the three types of TJR as deﬁned in CIHI hospitalization
data i.e., unilateral/bilateral, hip/knee, and with/without infection.
The procedure cost was calculated according to different cost
components of the hip/knee TJR surgery.
To estimate the future trend in terms of the number of TRJ
surgeries, we performed a regression analysis and projected the
total number of surgeries according to historical data from CJRR
using a linear regression method. We used the number of surgeries
estimated from the CJRR data for the years 2000e2010, extrapo-
lated them into the future and then calibrated the model by
adjusting the hazard ratio of hip/knee TJR surgery by age and sex
until the results from the model agreed with the extrapolated CJRR
data25. Details of method for projecting number of surgeries are
provided in Appendix A2. The costs for hip/knee TJRs were also
extrapolated for the next 20 years, separately for primary andrevision surgeries and for different age categories. There was a
change in the cost of TJR surgery over time, due to both changes in
the average length of stay (LOS) (which has decreased within the
last decade) and price inﬂation for CPWC reported in the CIHI
Hospital Price Index Report28. For this purpose, we projected the
average LOS for knee and hip replacement according to historical
data from the CJRR26 using an exponential model (Appendix A2).
Alternative care costs
A major component of the out-of-pocket cost of OA patients is
associated with visits to alternative care professionals including
physiotherapists, chiropractors and complementary care pro-
fessionals24. To estimate and project these costs in POHEM-OA, we
have used the MOH-OA dataset and developed a regression model
to estimate the probability and annual number of visits to alter-
native care professionals according to patients' age, sex and OA
stage (Appendix A1). The unit costs of visits to each alternative care
provider were then extracted from MSP dataset in 2003 and the
physician's price index rates were applied for projecting the rates
from 2010 to 203130.
Rehabilitation, out-of pocket, and side-effect of OA-related drugs
After the hip/knee TJR surgery, patients undergo different
rehabilitation routes depending on the disease severity and other
patient characteristics. For this, we have developed a separate
discharge destination model adapted from Coyte et al.32 and Old-
meadow et al.33. In addition to the health-system paid cost during
and after the hip/knee TJR, patients need to pay out-of-pocket for
some services including medical aid devices and formal caregiver
costs. We have included those costs in the model according to the
results from Gupta et al.34. The last cost component included in our
model is the cost associated with the side-effect of OA drugs. We
have included four types of side-effects of OA drugs including
stroke, cardiovascular diseases (CVD), serious gastrointestinal (GI)
complications, and dyspepsia. The lifetime cost of stroke and CVD
and the unit cost for GI complications and dyspepsiawere extracted
from the literature. Details are provided in Appendix A1.
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We have investigated the integrity of the results of our model
through two types of internal validation techniques: 1) Assigning
zero unit costs to physician, drugs, and hospital procedures (other
than hip/knee TJR surgery) and 2) Setting the probability of event-
based cost categories to zero for hip/knee TJR surgery, rehabilita-
tion, formal caregiver, side effect of drug costs and alternative care
costs. Further details of the internal validation are discussed in
Appendix A2.
Results
According to the POHEMmodel16, the size of the adult Canadian
population 20 years of age and older is projected to increase from
26.3 million in 2010 to 32.2 million in 2031 (22.5% increase). During
the same period, the OA population is forecast to rise from 3.6
million to almost 6 million (64% increase). OA prevalence for fe-
males is projected to increase from 0.16 to 0.21, while male prev-
alence is projected to increase from 0.11 to 0.16 throughout the
study period.
As shown in Fig. 2, we estimate that the total direct cost of OA
will rise from $2.9 billion dollars in 2010 to $7.6 billion in 2031, an
almost 2.6-fold increase in total OA-related direct costs. The in-
crease in the total direct cost reﬂects increase in prevalence and
utilization rates of the healthcare resources in addition to the
inﬂation rates for all healthcare resources. According to our results,
the extra direct cost associated solely with inﬂation in 2031 is
projected to be $2.4 billion, of which $1.8 billion is related to health
care system costs and $600 million to out-of-pocket costs.
Total direct cost by sex and age category
We estimate the direct costs of OA for females to be $0.71 billion
and $1.85 billion higher than those for males in 2010 and 2031,
respectively. As shown in Fig. 3, the share of female cost in both
out-of-pocket and healthcare system costs was higher than that of
males. The out-of-pocket cost for females and males associated
with OA in 2010 was $0.52 billion and $0.14 billion, respectively,
and increased to over $1.12 and $0.47 billion in 2031.
Female OA patients between 60 and 70 years of age constituted
the highest-cost group in 2010 (Fig. 4). However, the costs forFig. 2. Sex-speciﬁc and total direct cost of OA from 2010 to 2031. *All costs are discopatients in other age categories and the demography of the Cana-
dian population tend to change signiﬁcantly over the future de-
cades to a degree that, according to our results, OA patients aged
between 70 and 80 years will constitute the highest-cost age
category in 2031. For females, the change in the highest-cost age
category occurs in 2020 and for males in 2026. As shown in Fig. 4,
between 2025 and 2030, the costs for those aged 70e80 and 80e90
will increase at the highest rate compared to other age groups.
Total direct cost by cost component
Fig. 5 represents the out-of-pocket and healthcare system share
of the total direct cost of OA and the cost components associated
with each in 2010 and 2031. According to the POHEM-OA pro-
jections, from 2010 to 2031, the hospitalization costs of hip/knee
TJR surgeries would increase from $720 million dollars to almost
$2.8 billion dollars, while the overall costs for physicians, and
prescription drugs would increase from about $773 million to $1.9
billion. At the same time, the cost of side effects fromOA drugs rises
from $316 million to $665 million and out-of-pocket costs of pa-
tients including alternative care, over the counter drugs and other
out-of-pocket costs increase from $842 million to $1.92 billion
during the same period (Fig. 5).
While the dollar amounts of all the cost categories are projected
to increase during the study period, each cost category's share of
the total direct cost has shown a more complex trend, as shown in
Fig. 6. According to our model, the share of the overall costs for
physician, OTC drugs, and prescription drugs in addition to alter-
native care and formal caregiver costs is expected to decrease while
the share of hospitalization costs is expected to increase. The share
of rehabilitation and side effect costs is projected to remain stable
since 2010.
Discussion
In this study, we used an array of population-based data sources,
OA surveys and cost reports to estimate input parameters of a
validated individual-level simulation model (POHEM-OA) and then
project the costs of OA over the next 20 years from 2010 to 2031.
According to the POHEM-OA's projection, the overall direct cost of
OA will increase by almost 160%, from $2.9 billion ($842 million
out-of-pocket cost and $2.06 healthcare system expenditures) tounted back to 2010 $CAD using discount rates and are presented in billion dollars.
Fig. 3. Sex-speciﬁc healthcare system and out-of-pocket cost of OA. * All costs are in 2010 $CAD billion dollars.
Fig. 4. Total direct cost of OA by age category for males and females*. * Costs are in 2010 $CAD; age categories are as the followings: 0 to 49, 50 to 59, 60 to 69, 70 to 79, 80 to 89
and 90þ.
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system expenditures) in 2010 $CAD.
The increase in total cost of OA is due to increase in prevalence
and the average cost of the disease. According to our results, the
average cost of OA increased from $805 in 2010 ($234 out-of-pocket
and $571 healthcare system expenditures) to $1266 in 2031 ($320
out-of-pocket and $950 healthcare system expenditures) in 2010
$CAD. At the same time, the total number of people with OA
increased from 3.6 million to almost 6 million during the study
period. The average cost of OA has shown to be moderate, if not
high, compared to other chronic conditions1. For example, based on
our results, the average healthcare system expenditures of OA
($571) is relatively lower compared to other chronic diseases such
as CVD ($801) and cancer ($715) as estimated using administrative
data in Canada in $201035. On the other hand, prevalence of OA ishigh and it is increasing with a fast rate. Consequently, the com-
bination of moderate average cost and high and growing preva-
lence, makes OA an important health policy concern1.
We also described how the proportion of total cost of OA would
change across different cost components during the study period.
The share of hospitalization cost was the highest among all cost
components and increased from 25% to 37%, while physician visit,
drug and out-of-pocket cost constituted the next highest propor-
tion, respectively. Almost 95% of the hospitalization cost was due to
hip and knee TJR surgeries and 5% due to other hospital procedures
for OA patients. The increase in the cost of hip/knee TJR surgeries
was not only due to increase in the number of cases, but also due to
the high average cost because of high inﬂation rate for procedure
and prosthesis cost speciﬁc to this type of surgery. According to our
results, although the LOS after hip and knee TJRs will be decreasing
Fig. 5. Total direct cost of OA by cost categories in 2010 and 2031: out-of-pocket and healthcare system's costs. *Out-of-pocket share of the rehabilitation cost includes
rehabilitation and home care cost that is paid by patients and includes formal caregiver, home remodelling due to the disease and transportation cost during the year after the hip/
knee TJR surgery39; ** Healthcare system's share of the rehabilitation and home care cost that is paid by the government after the hip/knee TJR.; ^Other out-of-pocket costs includes
formal caregiver cost paid by the patients and community care services such as meals on wheels, transportation and home remodelling that are all paid before the hip/knee TJR
surgery.
Fig. 6. Cost components' share of the total direct cost from 2010 to 2031. *Hospitalization costs include those related to hip/knee total joint replacements (TJR's) and other OA-
related hospital procedures such as arthroscopy, shoulder TJR; ** Alternative care costs include those related to physiotherapy visits, chiropractor visits, and other alternative care
professionals; Formal caregiver cost includes paid caregiver cost in addition to community services cost such as home re-modelling due to the disease and transportation as listed in
Gupta et al.39.
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mostly due to its very high inﬂation rate.
The increasing number of TJR's is due to an increase in preva-
lence of OA and also due to policy decisions to increase capacity for
performing these types of surgeries36. While TJR has shown to be
highly cost-effective for those with severe OA37, recent studies have
shown an increasing rate of TJR's for those in less advanced stages
who may not beneﬁt from the procedure due to higher failure rates
and lower satisfaction38. Future studies using population health
models such as POHEM-OA need to assess the budgetary implica-
tions of different appropriateness criteria to limit the TJR for those
who do not beneﬁt39, while providemeans to encourage those who
beneﬁt the most from this procedure40.
With respect to age groups, our model suggests that those with
70e80 years of age will constitute the highest cost population in
2031. This underlines an important implication for evaluatingpolicies for OA care and management targeted at younger age
groups (e.g., 55e65 years in 2015) with mild OA in order to reduce
the burden among elderly with severe OA in the future (e.g., 70e80
in 2031)41. This is highlighted by the OARSI conservative OA care
and management guidelines for use of none-surgical care such as
weight reduction and muscle strengthening exercises in early and
mild stages of OA42.
Our study was not free of limitations. On top of the health-care-
sector inﬂation, the utilization rates for hospitalization, drugs, and
physicians have been also increasing during the past decade43. In
this study, we only implemented the increase in hospitalization
rates for the hip/knee TJR surgeries that was due to increase in both
incidence and policy-related decisions to increase the number of
surgeries. Other cost drivers, such as changes in the population age
and BMI distribution or increases in life expectancy of the popu-
lation, were also implemented in the POHEM-OA model16.
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and physician utilization in this study. While physician utilization
per capita (measured as total physician expenditure in constant
prices) have increased by around 25% from 1998 to 200843, the
increase in analgesics drugs was reported to be small in the same
interval43. In terms of the drugs included in our model, we did not
include newer analgesics, e.g., duloxetine, and intra-articular in-
jections of hyaluronic acid. We also did not include any drug
without conclusive evidence of effectiveness for general OA pop-
ulation, e.g., glucosamine44, and possible future drugs including
disease-modifying OA drug (DMOAD's). Future studies using
simulation models such as POHEM-OA can be used to address the
cost-effectiveness of such treatments45. Additional OA-related cost
components not included are nursing homes research costs and
rare side-effects such as chronic kidney failure, hepatic failure, or
addiction46.
One of the strength of our COI approach was use of a compre-
hensive cost listings of all resources used in addition to consider-
ation of heterogeneity of the population that reﬂected the intensity
of the resource used8. Traditional COI studies have been the target
of criticism since they use single data sources and they are not
capable of projecting the cost into the future8. According to the
Canadian Health Expenditure reports in 1994, the total direct OA
cost in Canada was projected to reach around $1.1e$1.6 billion
dollars in 201047, which is lower than our estimates. This is due to
the fact that none of the previous cost projections of OA included
both the BMI and demographic shifts among the Canadian popu-
lation16. Our result was close to another previous Canadian study
using a population database (rather than sample surveys) for the
overall direct cost of OA in 2006 ($2.1 billion in $2010 CAD)10.
However, it should be noted that none of the previous studies
included out-of-pocket costs for patients with OA.
While recent COI studies have used new techniques to estimate
incremental costs by performing regression-based analysis to
control for relevant comorbidities, there are limitations in these
methodologies that have caused large variations in the estimates of
total and average cost of OA8. For example, while several studies,
consistent with our results, have reported hospitalization costs as
the most expensive category of the total medical cost of OA5,6,10, a
Canadian study reported average cost of physician and outpatient
procedures to be slightly higher than the cost of hospitalization11.
Our results for the distribution of total cost of OA across different
cost categories, however, conforms to the recent study by Losina
et al.36, describing lifetime costs of knee OA in US. Losina et al.36
have shown that surgery and post-surgical cost is within 33e67%
of all the lifetime direct cost of knee OA across different eligibility
criteria for surgery deﬁned based on radiographic stages.
Estimating and projecting the cost of OA has been a methodo-
logical challenge in health economics literature when trying to
account for the complex interrelation of time varying risk factors
such as demographics and BMI shifts among the population48,49. In
this study, we performed a COI study with the use of MSM
modeling to project changes in the distribution of direct cost of OA
across different sub-populations and cost components. Constant
escalation of OA costs leads to growing demands for moremoney to
be devoted to arthritis care speciﬁcally among high cost sub-
populations including females and those over the age of 70 as
identiﬁed in this study. Given the magnitude of OA costs, small
decrease in risk factors or cost would help attenuate rising
healthcare expenditures in the near future.
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